{"entity":{"id":"denis-lacombe","kind":"person","name":"Denis Lacombe","aka":[],"tldr":"Denis Lacombe leads Europe's academic cancer trials organisation.","summary":"Denis Lacombe is Chief Executive Officer of the EORTC, Europe's academic cancer trials organisation. His specialisms are clinical trial methodology, academic research infrastructure and health policy. He has championed treatment-optimisation trials and pragmatic academic research alongside regulatory studies. His papers include a Nature Reviews Clinical Oncology piece on a European perspective for effective cancer drug development, an EORTC Brain Tumor Group phase II trial of sagopilone in recurrent glioblastoma, and the joint final report of EORTC 26951 and RTOG 9402 on procarbazine, lomustine and vincristine chemotherapy for anaplastic oligodendroglial tumours. His EORTC profile is linked.","asOf":"2026-09-08","links":[{"label":"EORTC","url":"https://www.eortc.org/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["curie-nki-eortc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Executive Officer, EORTC","institutionId":"curie-nki-eortc","specialisms":["Clinical trial methodology","Academic research infrastructure","Health policy"],"profiles":[{"label":"EORTC","url":"https://www.eortc.org/"}],"papers":[{"title":"European perspective for effective cancer drug development","journal":"Nature Reviews Clinical Oncology","year":2014,"doi":"10.1038/nrclinonc.2014.98"},{"title":"Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group","journal":"Annals of Oncology","year":2011,"doi":"10.1093/annonc/mdq729"},{"title":"Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors","journal":"Journal of Clinical Oncology","year":2022,"doi":"10.1200/jco.21.02543"},{"title":"Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma","journal":"New England Journal of Medicine","year":2005,"url":"https://doi.org/10.1056/NEJMoa043330","doi":"10.1056/NEJMoa043330"}],"orcid":"0009-0008-9094-393X"},"route":"/people/denis-lacombe/","neighbours":{"company":[{"id":"curie-nki-eortc","kind":"company","name":"EORTC","route":"/companies/curie-nki-eortc/"}],"paper":[{"id":"paper-stupp-temozolomide-nejm-2005","kind":"paper","name":"Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma","route":"/key-papers/paper-stupp-temozolomide-nejm-2005/"}]}}